What is the 13F Pro Quality Score for INSM?

13F Pro ranks INSMED Inc (INSM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View INSM's current score at https://13fpro.ai/research/INSM (free sign-up required for the full ranking).

Which hedge funds own the most INSM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of INSM include BlackRock,, Darwin Global Management, Ltd., FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/INSM as soon as new 13F filings post.

Where does 13F Pro source INSM data?

All INSMED Inc fundamentals and ownership data come directly from SEC EDGAR. INSMED Inc files with the SEC under CIK 1104506. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is INSM in?

INSMED Inc (INSM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is INSM research updated on 13F Pro?

INSM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

INSMED Inc(INSM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1104506 INSM stock profile & AI dashboard →

13F Pro Quality Score

29.4/100

Rank #2,409 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

91.9/100

Profitability

5.9/100

Balance Sheet

3.4/100

Earnings Quality

30.0/100

Free Cash Flow

5.8/100

Institutional Flow

8.4/100

Revenue Scale

41.1/100

Dilution Risk

7.4/100

INSM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for INSMED Inc (INSM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INSM at 29.4/100 on a 32-signal composite quality model, placing it at rank #2,409 of 2,879 stocks — the bottom half of the AI-ranked universe. INSM scores in the top quartile across revenue growth (91.9). Areas of concern include balance sheet strength (3.4) and free cash flow (5.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), INSMED Inc reports quarterly revenue of $306.0M, net income of $-163.6M, free cash flow of $-226.2M. Top institutional holders of INSM by reported 13-F value include BlackRock,, Darwin Global Management, Ltd., FMR, based on the most recent SEC filings. INSM trades on the Nasdaq exchange and files with the SEC under CIK 1104506. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INSM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for INSMED Inc directly from SEC EDGAR. INSMED Inc's 13F Pro composite quality score has ranged between 8 and 79 since 2021, currently 29.4 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about INSMED Inc

Quirks, history, and lore behind INSM — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · mid-cap · listed on Nasdaq · headquartered in New Jersey.
2
The Numbers
Annual revenue in the low hundreds of millions and climbing fast — but like most clinical-stage-turned-commercial biotechs, it has spent years running at a net loss while building its pipeline.
3
The History
Founded in 2000, it spent its early years as a quiet rare-disease researcher before landing a breakthrough therapy designation from the FDA and pivoting to commercial-stage operations.
4
The Secret
Its entire commercial bet is riding on one rare lung disease — a condition so uncommon that most doctors will never see a single patient with it in their career.
5
The Lore
The disease it targets, bronchiectasis caused by a rare infection, has been neglected for decades — making this company essentially the only game in town for patients who had no approved treatment.
6
The Giveaway
Its flagship drug Arikayce — an inhaled amikacin therapy — treats Mycobacterium avium complex (MAC) lung disease, a battle this Bridgewater biotech has been fighting almost alone.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$306.0M

Net Income

Q1 2026

$-163.6M

Free Cash Flow

Q1 2026

$-226.2M

D/E Ratio

Q1 2026

0.78

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+19.2% YoY

$363.7MFY 2024

FY21 $188.5MFY22 $245.4MFY23 $305.2MFY24 $363.7M

Net Income

-21.9% YoY

$-913.8MFY 2024

FY21 $-434.7MFY22 $-481.5MFY23 $-749.6MFY24 $-913.8M

Operating Income

-23.8% YoY

$-878.3MFY 2024

FY21 $-375.1MFY22 $-457.3MFY23 $-709.6MFY24 $-878.3M

EPS (Diluted)

-4.3% YoY

$-5.57FY 2024

FY21 $-3.88FY22 $-3.91FY23 $-5.34FY24 $-5.57

Total Assets

+52.3% YoY

$2.03BFY 2024

FY21 $1.24BFY22 $1.66BFY23 $1.33BFY24 $2.03B

Total Debt

-4.7% YoY

$1.12BFY 2024

FY21 $800.0MFY22 $1.15BFY23 $1.18BFY24 $1.12B

Op. Cash Flow

-27.5% YoY

$-683.9MFY 2024

FY21 $-363.3MFY22 $-400.4MFY23 $-536.2MFY24 $-683.9M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$363.7M +19.2%	$305.2M +24.4%	$245.4M +30.2%	$188.5M +14.6%	$164.4M +20.5%	$136.5M
Net Income	$-913.8M -21.9%	$-749.6M -55.7%	$-481.5M -10.8%	$-434.7M -47.8%	$-294.1M -15.6%	$-254.3M
Operating Income	$-878.3M -23.8%	$-709.6M -55.2%	$-457.3M -21.9%	$-375.1M -41.4%	$-265.2M -12.7%	$-235.2M
EPS (Diluted)	$-5.57 -4.3%	$-5.34 -36.6%	$-3.91 -0.8%	$-3.88 -28.9%	$-3.01 +0.0%	$-3.01
Total Assets	$2.03B +52.3%	$1.33B -19.7%	$1.66B +33.2%	$1.24B +56.2%	$796.2M +7.3%	$742.3M
Total Debt	$1.12B -4.7%	$1.18B +2.0%	$1.15B +44.3%	$800.0M +77.8%	$450.0M +0.0%	$450.0M
Operating Cash Flow	$-683.9M -27.5%	$-536.2M -33.9%	$-400.4M -10.2%	$-363.3M -65.6%	$-219.3M +12.5%	$-250.6M

Get alerted when INSM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for INSMED Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of INSM

BlackRock, Inc.
$2.7B16,678,146 sh
Darwin Global Management, Ltd.
$2.6B16,805,184 sh
FMR LLC
$2.2B13,160,167 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.7B10,371,802 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.6B9,642,131 sh
BAKER BROS. ADVISORS LP
$1.2B7,421,111 sh
Artisan Partners Limited Partnership
$1.1B6,527,301 sh
D. E. Shaw & Co., Inc.
$919.9M5,625,825 sh
Capital International Investors
$914.9M5,595,194 sh
STATE STREET CORP
$907.8M5,551,699 sh

Fund	Value	Shares
BlackRock, Inc.	$2.7B	16,678,146
Darwin Global Management, Ltd.	$2.6B	16,805,184
FMR LLC	$2.2B	13,160,167
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.7B	10,371,802
VANGUARD CAPITAL MANAGEMENT LLC	$1.6B	9,642,131
BAKER BROS. ADVISORS LP	$1.2B	7,421,111
Artisan Partners Limited Partnership	$1.1B	6,527,301
D. E. Shaw & Co., Inc.	$919.9M	5,625,825
Capital International Investors	$914.9M	5,595,194
STATE STREET CORP	$907.8M	5,551,699

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put INSM on your watchlist

Track score changes the day INSMED Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is INSM a good stock to buy?

13F Pro's AI-powered analysis of INSMED Inc (INSM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INSM are available on the INSM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own INSM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INSM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of INSMED Inc's investment landscape.